Company intelligence / Profile preview

Neurgain Technologies, Inc.

La Jolla, California, United Statesneurgaintech.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Neurgain’s lead programs use a proprietary subpial vector delivery platform for targeted gene therapy addressing chronic spasticity and neuropathic pain. The company has demonstrated preclinical proof-of-concept in animal models but has not reported human clinical results yet.

Therapeutic areas: Neurology
Modalities: Gene therapyCell therapyVector-based delivery systems
Industry: Biotech

Drug pipeline

5 assets

OpRegen

Phase 2

Indications: Geographic atrophy, Age-related macular degeneration

4 more assets in the full pipeline.

Partnerships

Welcomes licensing partnerships with organizations focused on neural conditions; specific partners not named as of now.

Beyond the preview

Go deeper on Neurgain Technologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurgain Technologies, Inc..